Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Megan Isaacson-Schmid

Physician Assistant, Medical Saint Louis, MO Physician Assistant

NPI 1124546726 CMS profile 10887939

520 S Elm Ave, Saint Louis, MO 63119

Open in the dashboard

General payments

$16,497

946 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Megan Isaacson-Schmid of Saint Louis, MO is reported in the CMS Open Payments database as having received $16,497 across 946 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,491 181
2024 General $4,024 205
2023 General $3,211 185
2022 General $3,195 189
2021 General $2,576 186

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Megan Isaacson-Schmid
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Megan Isaacson-Schmid were reported at $3,491. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Megan Isaacson-Schmid Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,576 $156 $41–$563 $132
2022 $3,195 $185 $55–$649 $149
2023 $3,211 $199 $58–$717 $160
2024 $4,024 $206 $62–$740 $164
2025 $3,491 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,582 142 payments
  2. Janssen Biotech, Inc. $2,523 145 payments
  3. Amgen Inc. $2,167 150 payments
  4. UCB, Inc. $1,623 79 payments
  5. Pfizer Inc. $1,507 96 payments
  6. Novartis Pharmaceuticals Corporation $1,487 92 payments
  7. Lilly USA, LLC $814 47 payments
  8. GlaxoSmithKline, LLC. $510 34 payments
  9. AstraZeneca Pharmaceuticals LP $416 23 payments
  10. Radius Health, Inc. $386 16 payments
  11. Other $2,482 122 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,325 943 payments
  2. Education $172 3 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,916 93 payments
  2. RINVOQ $1,895 102 payments
  3. XELJANZ $1,467 94 payments
  4. Cimzia $965 50 payments
  5. SIMPONI ARIA $915 72 payments
  6. COSENTYX Dermatology $883 54 payments
  7. TALTZ $814 47 payments
  8. COSENTYX Immunology $684 43 payments
  9. Bimzelx $659 29 payments
  10. REMICADE $631 53 payments
  11. Other $9,464 594 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,182

Median for Physician Assistant: 241

Drug cost

$517,101

Median for Physician Assistant: $4,110

Branded share of claims

28.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 27 $338,996
Rinvoq Upadacitinib Brand 12 $74,189
Actemra Actpen Tocilizumab Brand 11 $44,760
Savella Milnacipran Hcl Brand 24 $29,110
Leflunomide Generic 114 $8,721
Hydroxychloroquine Sulfate Generic 146 $6,692
Methotrexate Methotrexate Sodium Brand 238 $6,486
Sulfasalazine Dr Sulfasalazine Brand 22 $1,145
Azathioprine Generic 46 $1,124
Prednisone Generic 188 $1,039

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 33 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$590 — —
RINVOQ
$439 12 —
COSENTYX
$360 — —
Cimzia
$312 — —
XELJANZ
$247 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 33 with Patron

Records

946 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record